Home
/
Syndax Pharmaceuticals Inc
/
Financials
/
Quarterly
Syndax Pharmaceuticals Inc — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Syndax Pharmaceuticals Inc filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$45.87M
Nov 3, 2025
Q2
2025
Jun 30, 2025
$37.96M
Aug 4, 2025
Q1
2025
Mar 31, 2025
$20.04M
May 5, 2025
Q3
2025
Sep 30, 2024
$12.50M
Nov 3, 2025
Q2
2025
Jun 30, 2024
$3.50M
Aug 4, 2025
Q1
2025
Mar 31, 2024
$0
May 5, 2025
Q3
2024
Sep 30, 2023
$0
Nov 5, 2024
Q2
2024
Jun 30, 2023
$0
Aug 1, 2024
Q3
2022
Sep 30, 2021
$12.38M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$379.0K
Aug 8, 2022
Q1
2022
Mar 31, 2021
$379.0K
May 9, 2022
Q3
2021
Sep 30, 2020
$379.0K
Nov 15, 2021
Q2
2021
Jun 30, 2020
$379.0K
Aug 9, 2021
Q1
2021
Mar 31, 2020
$379.0K
May 11, 2021
Q3
2020
Sep 30, 2019
$379.0K
Nov 5, 2020
Q2
2020
Jun 30, 2019
$379.0K
Aug 6, 2020
Q1
2020
Mar 31, 2019
$379.0K
May 7, 2020
Q3
2019
Sep 30, 2018
$379.0K
Nov 7, 2019
Q2
2019
Jun 30, 2018
$379.0K
Aug 7, 2019
Q1
2019
Mar 31, 2018
$379.0K
May 8, 2019
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$379.0K
May 9, 2018
Q3
2017
Sep 30, 2017
$305.0K
Nov 8, 2017
Q2
2017
Jun 30, 2017
$305.0K
Aug 10, 2017
Q1
2018
Mar 31, 2017
$305.0K
May 9, 2018
Q3
2017
Sep 30, 2016
$305.0K
Nov 8, 2017
Q2
2017
Jun 30, 2016
$305.0K
Aug 10, 2017
Q1
2017
Mar 31, 2016
$305.0K
May 9, 2017
Q3
2016
Sep 30, 2015
$305.0K
Nov 14, 2016
Q2
2016
Jun 30, 2015
$17.0K
Aug 15, 2016
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($60.72M)
Nov 3, 2025
Q3
2025
Jun 30, 2025
($71.85M)
Nov 3, 2025
Q2
2025
Jun 30, 2025
($71.85M)
Aug 4, 2025
Q3
2025
Mar 31, 2025
($84.85M)
Nov 3, 2025
Q2
2025
Mar 31, 2025
($84.85M)
Aug 4, 2025
Q1
2025
Mar 31, 2025
($84.85M)
May 5, 2025
Q3
2025
Sep 30, 2024
($84.13M)
Nov 3, 2025
Q2
2025
Jun 30, 2024
($68.06M)
Aug 4, 2025
Q3
2025
Jun 30, 2024
($68.06M)
Nov 3, 2025
Q3
2025
Mar 31, 2024
($72.40M)
Nov 3, 2025
Q1
2025
Mar 31, 2024
($72.40M)
May 5, 2025
Q2
2025
Mar 31, 2024
($72.40M)
Aug 4, 2025
Q3
2024
Sep 30, 2023
($51.15M)
Nov 5, 2024
Q3
2024
Jun 30, 2023
($44.62M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($44.62M)
Aug 1, 2024
Q2
2024
Mar 31, 2023
($41.13M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($41.13M)
May 8, 2024
Q3
2024
Mar 31, 2023
($41.13M)
Nov 5, 2024
Q3
2023
Sep 30, 2022
($35.40M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($37.57M)
Aug 3, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($57.43M)
Nov 3, 2025
Q2
2025
Jun 30, 2025
($69.35M)
Aug 4, 2025
Q1
2025
Mar 31, 2025
($83.76M)
May 5, 2025
Q3
2025
Sep 30, 2024
($89.58M)
Nov 3, 2025
Q2
2025
Jun 30, 2024
($74.22M)
Aug 4, 2025
Q1
2025
Mar 31, 2024
($79.51M)
May 5, 2025
Q3
2024
Sep 30, 2023
($56.36M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($49.68M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($46.02M)
May 8, 2024
Q3
2023
Sep 30, 2022
($35.14M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($37.72M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($36.86M)
May 8, 2023
Q3
2022
Sep 30, 2021
($20.03M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($22.33M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($27.16M)
May 9, 2022
Q3
2021
Sep 30, 2020
($19.85M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($16.61M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($15.10M)
May 11, 2021
Q3
2020
Sep 30, 2019
($13.15M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($15.37M)
Aug 6, 2020